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Effect of ultrapure 
lipopolysaccharides derived from 
diverse bacterial species on the 
modulation of platelet activation
Thomas M. Vallance  1, Divyashree Ravishankar1, Dina A. I. Albadawi1, Harry Layfield1, 
Jonathan Sheard2,3, Rajendran Vaiyapuri4, Philip Dash5, Ketan patel5, Darius Widera  2 & 
Sakthivel Vaiyapuri1*
Platelets are small circulating blood cells that play essential roles in the maintenance of haemostasis 
via blood clotting. However, they also play critical roles in the regulation of innate immune responses. 
Inflammatory receptors, specifically Toll-like receptor (TLR)-4, have been reported to modify platelet 
reactivity. A plethora of studies have reported controversial functions of TLR4 in the modulation of 
platelet function using various chemotypes and preparations of its ligand, lipopolysaccharide (LPS). The 
method of preparation of LPS may explain these discrepancies however this is not fully understood. 
Hence, to determine the impact of LPS on platelet activation, we used ultrapure preparations of LPS 
from Escherichia coli (LPSec), Salmonella minnesota (LPSSM), and Rhodobacter sphaeroides (LPSRS) and 
examined their actions under diverse experimental conditions in human platelets. LPSec did not affect 
platelet activation markers such as inside-out signalling to integrin αIIbβ3 or P-selectin exposure upon 
agonist-induced activation in platelet-rich plasma or whole blood whereas LPSSM and LPSRS inhibited 
platelet activation under specific conditions at supraphysiological concentrations. Overall, our data 
demonstrate that platelet activation is not largely influenced by any of the ultrapure LPS chemotypes 
used in this study on their own except under certain conditions.
Platelets (small, circulating blood cells) are responsible for blood coagulation upon vascular injury although 
their unwarranted activation leads to thrombosis. Platelets also play critical roles in the regulation of innate 
immune responses through diverse molecular mechanisms1–4. Toll-like receptors (TLRs) are a group of immune 
receptors that recognise pathogen- (PAMP) and damage-associated molecular patterns (DAMP)5. In humans, 
TLR4 is expressed in various immune cells and it plays critical roles in the regulation of inflammatory responses. 
The high affinity ligand for TLR4 is lipopolysaccharide (LPS), a molecule that is found in the outer membrane 
of Gram-negative bacteria1,2. TLR4 may activate two different signalling pathways (the MyD88-dependent or 
-independent pathway) depending on the ligand involved, as demonstrated in a glioblastoma cell line6.
It has been widely reported that TLR4 is functional in platelets3,7. Moreover, various signalling molecules 
involved in the MyD88-dependent and -independent signalling pathways downstream of TLR4 have been 
reported to be present in platelets8,9 which also emphasise the notion that TLR4 is functional in platelets. The 
presence of signalling molecules involved in both pathways suggests the potential binding of TLR4 with different 
LPS chemotypes to trigger either MyD88-dependent or -independent signalling10. Binding of Escherichia coli LPS 
(LPSEC) to TLR4 has been reported to increase the level of fibrinogen binding on the surface of platelets under arte-
rial flow conditions7. Furthermore, circulating platelets have been reported to respond differently to diverse LPS 
chemotypes11. Moreover, it has been demonstrated that “rough (as referenced in the previous report – ‘without 
the O antigen’)” LPS [obtained from Salmonella minnesota (LPSSM)] is capable of enhancing platelet aggregation 
in PRP whereas “smooth (as referenced in the previous report - ‘with the O antigen’)” LPS (obtained from LPSEC) 
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has no effect12. This is also reflected in “rough” LPS significantly inducing the release of platelet-derived micropar-
ticles on its own and with agonist whilst “smooth” LPS had no significant effect12. Diverse platelet responses such 
as platelet-neutrophil interactions3, fibrinogen binding13, and sCD40L secretion14 have also been observed fol-
lowing stimulation by LPSEC although there is still no overall consensus on the LPS-induced effects in platelets2. 
For example, Claushuis et al.15 suggested that LPSEC is only capable of influencing mitochondrial respiration in 
platelets although they have reported a significant increase in P-selectin exposure on platelets obtained from sep-
tic patients15. Furthermore, Koessler et al.16 recently suggested that the preparation of platelets is a factor in the 
response to LPS as it could only potentiate platelet responses in washed platelets and not in platelet-rich plasma 
(PRP)16. The reasons for the discrepancies of the results reported in the previous studies7,13,15,17–19 are unclear 
although the inadequate purification of LPS may result in the presence of bacterial contaminants, such as cell wall 
components that act as TLR2 ligands, and might be responsible for the controversial results20,21.
In order to determine the impact of LPS chemotypes obtained from various bacterial species on the modula-
tion of platelet activation under different experimental settings, we used ultrapure LPSEC, LPSSM, and Rhodobacter 
sphaeroides (LPSRS, which is a TLR4 antagonist13,22,23) and analysed their effects in platelets. Here, we demonstrate 
the inability of ultrapure LPS chemotypes from various bacterial species to directly modulate platelet reactivity 
under diverse settings at physiological concentrations in contrast to conventionally prepared LPS.
Results
LpSec and LPSSM induce NF-κB activity in a reporter cell line. In order to confirm whether the 
ultrapure LPS chemotypes used in this study are functionally active and selective to TLR4, they were individually 
tested in U251-NF-κB-GFP-Luc cells, a reporter cell line for NF-κB signalling selectively via TLR4 (as they do 
not express TLR2)24. The results (Fig. 1) demonstrate that both LPSEC and LPSSM are able to significantly increase 
NF-κB activity whereas LPSRS did not affect this activity (as expected for a TLR4 antagonist) in comparison to the 
controls. Notably, no significant increase in NF-κB activity induced by LPSEC or LPSSM was seen in the presence of 
LPSRS. These data suggest that the LPS chemotypes used in this study are capable of ligating to TLR4 and induce 
its downstream signalling, and that LPSRS acts as an antagonist for TLR4.
TLR4 is prominently detected in activated platelets. The presence of TLR4 on the platelet surface 
has been described previously and its level has been reported to increase following platelet activation7,11,15,25,26. 
To corroborate the presence of TLR4 in platelets, immunoblotting was performed using human isolated platelets 
that were stimulated with 0.5 μg/mL CRP-XL [a potent agonist acting via platelet glycoprotein VI (GPVI)]27. The 
presence of TLR4 was predominantly detectable in activated platelets compared to the resting cells (Fig. 2A,B). 
Figure 1. Effect of LPS chemotypes on the U251-NF-κB-GFP-Luc reporter cell line. After 3.5 hours of 
starvation, the cells were incubated with or without 10 μg/mL LPSRS for 30 minutes. Then, U251-NF-κB-GFP-
Luc cells were treated with 1 μg/mL LPSEC or 1 μg/mL LPSSM for 24 hours before lysis and measurement of 
luciferase activity by spectrophotometry. The results were normalised to the mean of vehicle control treated 
cells or the mean of the LPSRS control. The data represent percentage change from control ± S.D. (n = 6). The 
p values shown are as calculated by a one-way ANOVA with Bonferroni’s post-hoc test (***p < 0.001, and 
****p < 0.0001).
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The selectivity of TLR4 antibody used was confirmed using U251-NF-κB-GFP-Luc cell lysates as a positive 
control and HEK293 lysates as a negative control (Fig. S1A). The increased level of TLR4 was also detected in 
platelets that were stimulated with 0.5 μg/mL collagen (Fig. S1B). Furthermore, the presence of TLR4 was con-
firmed through immunostaining of platelets (Fig. 2C) where a significant increase on the surface of platelets was 
observed upon activation with 0.5 μg/mL CRP-XL (Fig. 2D).
LpSec does not affect platelet activation. To investigate the effect of different ultrapure LPS chemotypes 
on platelet activation, flow cytometry-based assays were performed to measure the levels of fibrinogen binding 
(a marker for inside-out signalling to αIIbβ328) and P-selectin exposure (a marker for α-granule secretion1,29). 
As TLR4 signalling in platelets was generally considered as pro-inflammatory, we hypothesised that LPSEC may 
directly activate platelets. Therefore, LPSEC was initially tested in platelets in the absence of an agonist7,13,18. The 
effect of diverse concentrations of (0.125 μg/mL–2 μg/mL) ultrapure LPSEC on platelet activation was determined 
using human PRP or whole blood under different conditions such as various temperature and incubation times. 
The conditions tested were: incubation of PRP with LPSEC at room temperature for 20 (Fig. 3A,B) or 25 minutes 
(Fig. S2A,B), and incubation of PRP with LPSEC at 37 °C for 25 (Fig. 3C,D) or 50 minutes (Fig. S2C,D). These 
results demonstrate that LPSEC does not induce platelet activation in PRP as measured by the levels of fibrinogen 
binding and P-selectin exposure at these conditions. To determine whether LPSEC has priming roles on platelets 
as reported previously30, its effect on CRP-XL-activated platelets (Fig. 3E,F) was analysed through preincubat-
ing it for 5 minutes with PRP prior to stimulation with 0.5 μg/mL CRP-XL for 20 minutes at room temperature. 
Again, the LPSEC failed to increase the level of CRP-XL-induced platelet activation. Furthermore, whole human 
blood was used to investigate the effect of LPSEC on platelet activation in the presence of other blood cells but no 
significant change was observed (Fig. 3G,H). Together, these data demonstrate that ultrapure LPSEC was unable to 
significantly increase either the level of fibrinogen binding or P-selectin exposure on human platelets under any of 
the conditions tested in this study. However, the non-ultrapure version of LPSEC was able to significantly increase 
fibrinogen binding in platelets under similar conditions without the presence of a platelet agonist (Fig. S2E). In 
contrast, PRP from the same donors did not respond to ultrapure LPSEC (Fig. S2E).
Figure 2. Expression of TLR4 in platelets. (A) Resting (−) and CRP-XL (0.5 μg/mL) activated (+) platelets 
were examined for the presence of TLR4 via immunoblotting. The level of α-tubulin was detected as a loading 
control. The blot shown is representative of five separate experiments using platelets obtained from five separate 
donors. (B) Quantification of the presence of TLR4 in platelet lysates compared to the expression of α-tubulin 
using immunoblots. Data represent mean ± S.D. and the p value was calculated using Student’s t-test (n = 5, 
**p < 0.01). (C) The level of TLR4 expression on resting and 0.5 μg/mL CRP-XL activated platelets was analysed 
by confocal microscopy using a 100x objective. The platelets are shown in magenta and the TLR4 is displayed 
in cyan. The images shown are representative of data obtained from three separate individuals. The scale 
bar represents 10 μm. (D) Quantification of the level of TLR4 in confocal microscopy images obtained from 
different donors. Three different regions of three images for each donor were analysed for the presence of TLR4 
clusters and presented as mean ± S.D. P value (*p < 0.05) was calculated using Student’s t-test.
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LpSSM modulates platelet activation at specific conditions. A previous report using U251-NFκB-A1 
cells has suggested that ultrapure LPSSM possesses the capacity to bias signalling mediated by TLR4 towards the 
MyD88-independent pathway6. In order to determine the effect of LPSSM on platelets, various concentrations of 
this LPS were tested on the modulation of platelet activation upon stimulation with CRP-XL. Similar to above 
experiments with LPSEC, the levels of fibrinogen binding and P-selectin exposure were measured in platelets upon 
treatment with LPSSM in the presence and absence of CRP-XL.
To determine the effect of LPSSM on platelets in the absence of an agonist, PRP that was incubated with 2 μg/
mL LPSSM was analysed along with CRP-XL-activated platelets as a control in different experimental conditions. 
The results (Fig. 4A–H) demonstrate that LPSSM does not instigate platelet activation in isolation.
To investigate whether LPSSM has any modulatory effects on the agonist-induced platelet activation, platelets 
were treated with LPSSM and 0.5 μg/mL CRP-XL simultaneously at room temperature for 20 minutes. These results 
(Fig. 4A,B) suggest that LPSSM does not affect CRP-XL-induced platelet activation when they were treated simul-
taneously at room temperature. Subsequently, the platelets were stimulated with a low (0.25 μg/mL) concentration 
of CRP-XL (Fig. S3A,B) and LPSSM. Again, LPSSM did not affect platelet activation induced by a low agonist con-
centration. Similarly, to investigate whether preincubation of platelets with LPSSM affects agonist-induced platelet 
responses, PRP was preincubated with LPSSM for 5 minutes at room temperature prior to activation with 0.5 μg/
mL CRP-XL but again this did not affect platelet function (Fig. S3C,D).
Many previous studies reporting the ability of LPS to modulate platelet function were conducted at room 
temperature13,15,18,29. To make the experiments more physiologically relevant, the platelets were incubated at 37 °C. 
This enabled the investigation of whether temperature was a factor conferring the modulation of platelet activa-
tion by LPSSM. The data obtained with platelets that were preincubated at 37 °C for 5 minutes with LPSSM followed 
by 20 minutes of stimulation with 0.5 μg/mL CRP-XL at 37 °C suggest that LPSSM did not alter platelet activity 
Figure 3. Effect of LPSEC on platelet activation. The level of fibrinogen binding (as a marker for inside-out 
signalling to integrin αIIbβ3) (A) and the level of P-selectin exposure (as a marker for α-granule secretion) (B) 
was measured in PRP upon incubation with LPSEC for 20 minutes at room temperature (n = 4). In order to 
determine the impact of temperature on LPS-induced effects in platelets, the level of fibrinogen binding (C) and 
P-selectin exposure (D) in PRP was measured by incubating PRP with LPSEC for 25 minutes at 37 °C (n = 5). 
To determine if the LPS chemotypes possess priming effects in platelets, the level of fibrinogen binding (E) 
and P-selectin exposure (F) was measured in PRP upon preincubation with LPSEC for 5 minutes followed by 
stimulation with a vehicle control or 0.5 μg/mL CRP-XL for 20 minutes at 37 °C (n = 3). Similarly, the level of 
fibrinogen binding (G) and P-selectin exposure (H) in human whole blood was measured upon incubation with 
LPSEC for 25 minutes at 37 °C (n = 3). The data were normalised to either their resting control (100%: A–D and 
G,H) or their 0.5 μg/mL CRP-XL control (100%; E,F) and analysed using one-way ANOVA and Dunnett’s post-
hoc test. Data represent mean ± S.D. 2 EC - 2 μg/mL LPSEC. 
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(Fig. 4C,D) under these conditions. To determine the impact of incubation time on LPSSM-induced effects, the pre-
incubation times were increased from 5 minutes to 30 minutes. The increase in preincubation time did not enable 
LPSSM to significantly affect fibrinogen binding (Fig. 4E) although, P-selectin exposure stimulated by 0.5 μg/mL 
CRP-XL was significantly reduced (by approximately 5%) only at a concentration of 2 μg/mL LPSSM (Fig. 4F). At 
higher concentrations of LPSSM, with 10 minutes of pre-incubation at 37 °C, LPSSM was unable to influence fibrin-
ogen binding or P-selectin exposure induced by CRP-XL (Fig. S3E,F). However, under these conditions, 5 μg/mL 
LPSSM was able to significantly potentiate (by around 30%) the P-selectin exposure induced by 10 μM TRAP-6 
but fibrinogen binding was unaffected (Fig. S3G,H). Moreover, ADP-induced fibrinogen binding and P-selectin 
exposure were unaffected by LPSSM (Fig. S3I,J). Furthermore, whole human blood was used to investigate the effect 
of LPSSM on platelet activation. The whole human blood was incubated with LPSSM for 5 minutes at 37 °C prior to 
platelet activation by 0.5 μg/mL CRP-XL for 20 minutes at 37 °C but it did not affect platelet activation in whole 
blood (Fig. 4G,H). In conclusion, while 2 μg/mL LPSSM is capable of significantly inhibiting (only by around 5%) 
CRP-XL-induced P-selectin exposure on the platelet surface under specific conditions (PRP; 30 minutes of prein-
cubation at 37 °C), in general, LPSSM did not affect platelet function under any of the conditions tested in this study.
LpSRS inhibits platelet activation at specific conditions. LPSRS has been suggested to be an antagonist 
for TLR413,22,23. Here, the effect of ultrapure LPSRS was investigated upon activation of platelets with CRP-XL by 
measuring the level of fibrinogen binding and P-selectin exposure using flow cytometry. LPSRS was tested in the 
absence of a TLR4 agonist to investigate potential endogenous activity of the receptor as previous work has sug-
gested that some TLR4 molecules are in an active conformation in unstimulated cells23. Furthermore, endogenous 
Figure 4. Effect of LPSSM on platelet activation. To determine the impact of LPSSM on the modulation of platelet 
activation, the level of fibrinogen binding (A) and P-selectin exposure (B) was analysed in PRP in the presence 
of different concentrations of LPSSM and 0.5 μg/mL CRP-XL after simultaneous incubation for 20 minutes at 
room temperature (n = 5). To determine the impact of temperature on LPS-mediated effects in platelets, the 
level of fibrinogen binding (C) and P-selectin exposure (D) in PRP was measured upon preincubation with 
LPSSM for 5 minutes followed by stimulation with 0.5 μg/mL CRP-XL for 20 minutes at 37 °C (n = 6). Similarly, 
the preincubation of PRP with LPSSM was increased to 30 minutes prior to stimulation with 0.5 μg/mL CRP-XL 
for 20 minutes at 37 °C, and the level of fibrinogen binding (E) and P-selectin exposure (F) was analysed 
(n = 4). Furthermore, the level of fibrinogen binding (G) and P-selectin exposure (H) was analysed in human 
whole blood upon preincubation with LPSSM for 5 minutes followed by stimulation with 0.5 μg/mL CRP-XL 
for 20 minutes at 37 °C (n = 3). The data were normalised to their 0.5 μg/mL CRP-XL control, and the p value 
(**p < 0.01) shown was calculated using one-way ANOVA and Dunnett’s post-hoc test. Data represent mean ± 
S.D. The samples treated in the absence of 0.5 μg/mL CRP-XL are represented with empty bars.
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ligands, such as high mobility group box 1 (HMGB1), have been suggested to activate TLR431,32. Similar to LPSSM, 
LPSRS was tested in resting platelets in all the conditions used in the above experiments (Fig. 5A–H) and the 
results demonstrate that LPSRS is unable to significantly alter platelet activation in resting platelets.
To determine the impact of LPSRS on agonist-induced platelet activation, platelets were incubated simulta-
neously with LPSRS and 0.5 μg/mL CRP-XL for 20 minutes at room temperature (Fig. 5A,B) and the levels of 
fibrinogen binding and P-selectin exposure were measured. The results show that LPSRS did not significantly 
inhibit P-selectin exposure or fibrinogen binding under these conditions. LPSRS was also tested in conjunction 
with the lower concentration of CRP-XL (0.25 μg/mL) under the same conditions (Fig. S4A,B). However, it was 
unable to significantly inhibit platelet activation at this concentration of CRP-XL. Platelets were also preincubated 
with LPSRS at room temperature for 5 minutes (Fig. S4C,D) before stimulation with CRP-XL (0.5 μg/mL) but it 
did not alter platelet activation under these conditions. The influence of LPSRS was also tested at 37 °C (Fig. 5C,D) 
with 5 minutes of preincubation with LPSRS followed by 20 minutes stimulation with 0.5 μg/mL CRP-XL and it 
did not affect platelet activation. When the preincubation time was increased to 30 minutes, although the level of 
fibrinogen binding was unaffected under these conditions (Fig. 5E), a significant decrease (approximately 10%) 
in P-selectin exposure induced by 0.5 μg/mL CRP-XL (Fig. 5F) was observed. The effect of LPSRS on platelet acti-
vation in whole blood was examined. Although a decrease in fibrinogen binding was observed (approximately 
20%, Fig. 5G), no significant inhibition of P-selectin exposure (Fig. 5H) was observed following 5 minutes of 
preincubation with LPSRS and 20 minutes of stimulation with CRP-XL at 37 °C. Together, these data demonstrate 
that ultrapure LPSRS is able to significantly inhibit P-selectin exposure (α-granule secretion in PRP) following 
Figure 5. Effect of LPSRS on platelet activation. To determine the impact of LPSRS on the modulation of platelet 
activation, the level of fibrinogen binding (A) and P-selectin exposure (B) was analysed in PRP in the presence 
of different concentrations of LPSRS and 0.5 μg/mL CRP-XL after incubation for 20 minutes at room temperature 
(n = 4). To determine the impact of temperature on LPS-mediated effects in platelets, the level of fibrinogen 
binding (C) and P-selectin exposure (D) in PRP was measured upon preincubation with LPSRS for 5 minutes 
followed by stimulation with 0.5 μg/mL CRP-XL for 20 minutes at 37 °C (n = 6). Similarly, the preincubation 
of PRP with LPSRS was increased to 30 minutes prior to stimulation with 0.5 μg/mL CRP-XL for 20 minutes at 
37 °C, and the level of fibrinogen binding (E) and P-selectin exposure (F) was analysed (n = 5). Furthermore, 
the level of fibrinogen binding (G) and P-selectin exposure (H) was analysed in human whole blood upon 
preincubation with LPSRS for 5 minutes followed by stimulation with 0.5 μg/mL CRP-XL for 20 minutes at 37 °C 
(n = 3). The data were normalised to their 0.5 μg/mL CRP-XL control, and the p value (*p ≤ 0.05) shown is as 
calculated using one-way ANOVA and Dunnett’s post-hoc test. Data represent mean ± S.D. The samples treated 
in the absence of 0.5 μg/mL CRP-XL are represented with empty bars.
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30 minutes preincubation, and inside-out signalling to integrin αIIbβ3 in whole blood, but in other conditions, 
LPSRS does not alter platelet activation either directly or upon activation with a platelet agonist.
Moreover, following 10 minutes of preincubation with ultrapure LPSRS, platelet fibrinogen binding and 
P-selectin exposure induced by 0.5 μg/mL CRP-XL (S4E-F), 10 μM TRAP-6 (S4G-H), and 10 μM ADP (S4I-J) 
were unaffected by the presence of ultrapure LPSRS. Interestingly, when these experiments were repeated using a 
non-ultrapure version of LPSRS, fibrinogen binding (but not P-selectin exposure) induced by 0.5 μg/mL CRP-XL 
was potentiated by 5 μg/mL LPSRS (Fig. S4K,L). Furthermore, no significant change in responses evoked by 
10 μM TRAP-6 was observed in fibrinogen binding and P-selectin exposure (Fig. S4M,N). However, a significant 
increase was observed in P-selectin exposure (but not fibrinogen binding) in platelets induced by 10 μM ADP 
in the presence of 10 μg/mL LPSRS (Fig. S4O,P). This provides further evidence that there may be a contaminant 
present in these non-ultrapure versions of LPS that may be responsible for stimulating platelet activity.
LPS does not affect aggregation of pre-activated platelets. As the availability of TLR4 on the plate-
let surface has been suggested to increase upon platelet activation11,26, platelets were pre-activated with a low con-
centration of ADP (0.5 μM) prior to treatment with LPSEC, LPSSM, or LPSRS and further activation with a higher 
dose of ADP (4 μM) (Fig. 6A). The results (Fig. 6B,C) suggest that none of the three ultrapure LPS chemotypes 
are capable of significantly modifying the aggregation of platelets under these conditions. Similar results were 
obtained when the experiment was conducted, using the same procedure, with 0.1 μg/mL collagen (low dose) 
and 0.25 μg/mL collagen (high dose; Fig. 6D,E) or 1 μM TRAP-6 (low dose) and 10 μM TRAP-6 (high dose; 
Fig. 6F,G). These data suggest that priming platelets did not affect the ability of LPS chemotypes to modulate 
platelet function.
LPS does not exert cytotoxic effects in platelets. To determine if the ultrapure LPS chemotypes used 
in this study exert toxic effects in platelets, various concentrations of LPS chemotypes were analysed in platelets 
using a lactate dehydrogenase (LDH) assay. The results suggest that the LPS chemotypes [LPSEC (Fig. S5A), LPSSM 
(Fig. S5B), and LPSRS (Fig. S5C)] at the concentrations used in this study were unable to induce cytotoxicity in 
platelets. The results demonstrate that ultrapure LPS chemotypes do not induce any direct cytotoxic effects on 
platelets.
Discussion
Several studies have reported controversial results on the effects of LPS (specifically LPSEC) on platelet function. 
A key source of criticism revolves around the potential contamination of LPS preparations, possibly by cell wall 
components that may stimulate TLR2, and the interference of these contaminants on platelet reactivity20. The 
structure of LPS varies between chemotypes and these structural differences have been proposed to be responsi-
ble for conferring different downstream activities10,11,33. In order to address some of these previous concerns and 
to determine the precise actions of LPS on platelets, we determined the impact of ultrapure LPS chemotypes from 
various bacterial species on the modulation of platelet activation.
Initially, the activity of LPS chemotypes was analysed using an NF-κB reporter cell line (which selectively 
express TLR4 and lack TLR2) to confirm their ability to selectivity bind TLR4 and induce downstream signal-
ling. Our results demonstrate that both ultrapure LPSEC and LPSSM are capable of increasing luciferase activity in 
U251-NF-κB-GFP-Luc cells compared to the controls whereas LPSRS did not affect the activity as it is an antag-
onist for TLR423. Moreover, LPSEC and LPSSM were incapable of significantly inducing signalling to NFκB in the 
presence of LPSRS. Similar results were reported in a previous study to demonstrate the impact of ultrapure LPS 
chemotypes in the modulation of luciferase activity in the same cell type24.
The expression of TLR4 on the platelet surface has been widely reported and indeed, in some studies this 
has been reported to increase upon activation of platelets by a diverse range of agonists including thrombin, 
convulxin, TRAP-6, ADP, and adrenaline11,16,26. Here, we also demonstrate that platelets express low levels of 
TLR4 on the surface at resting conditions, however its level increases following activation with agonists such as 
CRP-XL and collagen. Moreover, Tsai et al.26 suggested that in resting platelets, TLR4 is associated with myosin-9 
in the intracellular α-granules, and during activation by thrombin, calpain (a protease) is activated and it cleaves 
the interactions between these two proteins and liberates TLR4 enabling its transport to the platelet surface. 
Consistent with this previous study, we demonstrate that TLR4 (at 94 kDa) was only prominently detectable 
in activated platelets. The resting platelets may contain TLR4, however, if it is associated with myosin-9 in 
α-granules, it may possess a greater molecular mass. Thus, it is not expected to appear at 94 kDa. Furthermore, 
this would suggest that the preincubation of TLR ligands is superfluous as there may not be a substantial number 
of TLR4 receptors present on the platelet surface. Moreover, the level of platelet activation by agonists could be 
a key factor for TLR4 exposure on the cell surface. However, we demonstrate that LPSRS and LPSSM treatments 
required 30 minutes of preincubation at 37 °C before a significant (~10%) decrease in P-selectin exposure was 
observed at a supraphysiological concentration under specific conditions.
Previously, it has been reported that LPSEC can enhance platelet aggregation13,18 and alter the release of differ-
ent cytokines11,29. Furthermore, NF-ĸB (the transcription factor activated downstream of the MyD88-dependent 
pathway) is involved in platelet activation induced by classical platelet agonists2,6,34. Notably, platelets obtained 
from TLR4-deficient mice have been shown to possess similar aggregation behaviour compared to control mouse 
platelets35. Currently, there is no consensus regarding platelet response to LPSEC as some reports suggest that 
it can induce P-selectin exposure and fibrinogen binding7,13,18,30 whereas others suggest that it does not11,15,17. 
Ultrapure LPSEC has been used by Berthet et al.11 and Claushuis et al.15 where there was no significant increase in 
P-selectin exposure observed. In line with these previous studies, here we also report that LPSEC does not mod-
ulate platelet activation under the diverse settings used in this study. However, a non-ultrapure version of LPSEC 
did induce a significant increase in the binding of fibrinogen to platelets which supports the hypothesis that the 
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Figure 6. Effect of pre-activation of platelets on the LPS-mediated actions. Aggregometry was used to determine 
the effect of mild pre-activation by a low dose of different platelet agonists on LPS-modulated actions in PRP.  
(A) demonstrates the schematic protocol for this experiment. A representative trace demonstrating the aggregation 
induced by ADP in the presence of a vehicle control or 1 μg/mL LPSSM is shown in (B). The extent of activation 
by 4 μM ADP following pre-activation with 0.5 μM ADP and treatment with vehicle, 1 μg/mL LPSEC, 1 μg/mL 
LPSSM, or 10 μg/mL LPSRS is shown in (C). (D) A representative aggregation curve induced by 0.25 μg/mL  
collagen in PRP following pre-activation by 0.1 μg/mL and incubation with a vehicle control or 1 μg/mL LPSSM. 
(E) Shows the normalised results for this experiment. (F) A representative trace of aggregation induced by 
10 μM TRAP-6 following pre-activation with 1 μM TRAP-6 and incubation with a vehicle control or 1 μg/mL 
LPSSM. The normalised aggregation response for this experiment is shown in (G). In all traces, the LPS-treated 
trace is represented in black whilst the vehicle is represented in grey. Data represent mean ± S.D. (n = 3) and 
were analysed using one-way ANOVA.
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contaminants found in LPS preparation may be responsible for inducing the observed effects in platelets. The 
incubation times and concentrations of LPSEC (0.125 μg/mL and 2 μg/mL) used in this study are comparable to 
other studies where they have used concentrations ranging from 100 ng/mL15 to 500 ng/mL29, 1 μg/mL13,18,36 to 
3 μg/mL11, and 5 μg/mL3,7 to 10 μg/mL30.
Moreover, LPSSM did not affect fibrinogen binding and P-selectin exposure in the absence of a platelet agonist. 
The preincubation (30 minutes) of LPSSM with platelets was able to significantly reduce agonist-induced P-selectin 
exposure (but only by around 5%) suggesting that α-granule secretion may be inhibited at supraphysiological 
concentrations of LPSSM. Moreover, the level of fibrinogen binding was unaffected by LPSSM under any of the 
conditions tested.
LPSRS was also tested for its effects on platelet activity under similar conditions to LPSSM but it did not display 
any significant effects in the absence of a platelet agonist. However, it affected α-granule secretion but only at sup-
raphysiological concentrations after 30 minutes of preincubation in the PRP. Conversely, the non-ultrapure LPSRS 
significantly increased fibrinogen binding to platelets upon activation with CRP-XL and P-selectin exposure on 
platelets upon activation with ADP, which suggests that another factor may be present in the non-ultrapure ver-
sion that induces the effects reported here and in other studies. To investigate whether pre-activation of platelets 
would augment TLR4-mediated effects, a low dose of agonist (ADP, TRAP-6, or collagen) was used to prime 
platelets prior to LPS treatment and further stimulation with a greater concentration of the same agonist. These 
experiments did not lead to an increase in the effect induced by any of the LPS chemotypes used.
Under pathological conditions such as in sepsis, a plethora of factors are present in the bloodstream and they 
may be responsible for the observed in vivo effects of LPS on platelets. This could be explained by synergistic 
effects that were not tested in this study although this was suggested by other studies15,19,37. In addition to plate-
lets, many other immune cells present in the blood may also respond to LPS and interact with platelets thereby 
augmenting their activity1,3,38. Despite the presence of immune cells in the whole blood, the results from this 
study suggest that the LPSEC and LPSSM treatment is unable to alter fibrinogen binding or P-selectin exposure on 
platelets in whole blood. However, LPSRS was capable of modulating inside-out signalling to integrin αIIbβ3, but 
not α-granule secretion following stimulation with an agonist at specific concentrations.
Overall, we conclude that the actions of LPS chemotypes on platelets may not be direct and, during patholog-
ical conditions, this may be driven or augmented through other molecules that are released under those circum-
stances. Moreover, the purity of LPS must be ensured prior to testing them in platelets either through a reporter 
cell line or other experiments to confirm their selectivity to TLR4 and the absence of potential impurities for 
other molecules. It is important that physiological effects mediated via other receptors, such as TLR2, are not 
misinterpreted as TLR4-specific effects. This will ensure that solid foundations are available for clinical research, 
as TLR4 remains an attractive target for certain immunological diseases. The results presented in this study will 
form a strong basis for future studies to investigate the impact of different LPS chemotypes on the modulation of 
platelet function, haemostasis, and thrombosis under diverse pathophysiological settings.
Methods
Materials. Ultrapure lipopolysaccharides (LPS) from Escherichia coli O111:B4, Salmonella minnesota 
R595, and Rhodobacter sphaeroides and their non-ultrapure alternatives (where available) were purchased from 
InvivoGen, France and used throughout all the experiments. Ultrapure versions of LPS were purified by an addi-
tional phenol-TEA-DOC step compared to the non-ultrapure versions that underwent extraction via a phe-
nol-water mixture21.
Human blood collection and platelet preparation. The blood was obtained from healthy human vol-
unteers with informed consent in accordance to the procedures approved by the University of Reading Research 
Ethics Committee (UREC: 17/17), and the platelets were prepared as described previously39–42. All methods were 
performed in accordance with the relevant institutional and national guidelines and regulations. Briefly, the blood 
was drawn via venepuncture into vacutainers containing 3.2% (w/v) citrate and used in assays where whole blood 
was required. For the preparation of platelet-rich plasma (PRP), the blood was centrifuged at 102 g for 20 minutes 
at 20 °C and the PRP was carefully collected for further experiments. For the preparation of isolated platelets, the 
blood was mixed with 15% (v/v) acid citrate dextrose [ACD: 2.5% (w/v) sodium citrate, 2% (w/v) glucose and 1.5% 
(w/v) citric acid] prior to centrifugation at 102 g for 20 minutes at 20 °C. The PRP was then collected and centrifuged 
at 1413 g for 10 minutes at 20 °C in the presence of 50 ng/mL prostaglandin I2 (PGI2) before the plasma was removed 
and the platelet pellet was resuspended in modified Tyrode’s-HEPES buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM 
Na2HPO4.12H2O, 12 mM NaHCO3, 20 mM HEPES, 1 mM MgCl2, and 5 mM D-glucose, pH 7.3) with 12% (v/v) 
ACD. Following another centrifugation at 1413 g for 10 minutes in the presence of 50 ng/mL PGI2, the platelet pellet 
was resuspended in fresh modified Tyrode’s-HEPES buffer and left to rest for 30 minutes at 30 °C prior to use.
Cell culture and luciferase assay. The U251-NF-κB-GFP-Luc cells24 grown in high glucose DMEM sup-
plemented with 10% (v/v) foetal calf serum (FCS) and 2 mM L-glutamine (Sigma Aldrich, UK) were seeded on 
a 24-well plate at 1 × 105 cells/well and left in a 37 °C humidified incubator with 5% CO2 until >80% conflu-
ency was achieved. The cells were then starved in serum-free high glucose DMEM supplemented with 2 mM 
L-glutamine for 3.5 hours prior to addition of vehicle (endotoxin-free water) or 10 μg/mL LPSRS for 30 minutes. 
Subsequently, cells were treated with a vehicle control, 1 μg/mL LPSEC, 1 μg/mL LPSSM, or 10 μg/mL LPSRS (or their 
combinations). After 24 hours, the cells were washed with sterile phosphate-buffered saline (PBS) (Sigma Aldrich, 
UK) before being lysed on a rocker in cell culture lysis buffer (Promega, UK) for one hour at room temperature. 
The cell lysates were centrifuged for 5 minutes at 5000 g at room temperature. The level of luciferase activity of 
each lysate after the addition of luciferase assay substrate (Promega, UK) was measured by a SpectraMax iD3 
multi-mode microplate reader (Molecular Devices, USA).
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Immunocytochemistry. The isolated human platelets were suspended in modified Tyrode’s-HEPES buffer 
containing 10 μM Cell Tracker, CMAC (Thermo Fisher Scientific, UK) for one hour. The platelets were mixed on 
a rotational plate shaker at 330 rpm for 10 minutes at room temperature in the presence of 0.5 μg/mL cross-linked 
collagen-related peptide (CRP-XL) (obtained from Professor Richard Farndale, University of Cambridge, UK) 
or modified Tyrode’s buffer as a control before they were fixed by the addition of 0.2% (v/v) formyl saline. The 
platelets were centrifuged at 2500 g for 5 minutes, washed in PBS, then resuspended in 5% goat serum in PBS for 
blocking for 30 minutes. After blocking, the platelets were washed with PBS and resuspended in 1/100 anti-TLR4 
[76B357.1] antibody (Abcam, UK) in PBS and incubated for one hour prior to washing and incubating with 1/300 
goat anti-mouse Alexa Fluor 647-conjugated secondary antibody for one hour. Subsequently, the platelets were 
washed, resuspended in Mowiol [containing 0.1% (v/v) 1,4-phenylenediamine dihydrochloride], and mounted 
on a microscope slide. A Nikon A1-R Confocal Microscope was used for image acquisition using a 100x objective. 
The level of expression of TLR4 was quantified using ImageJ.
Immunoblotting. The isolated human platelets were treated with either modified Tyrode’s-HEPES buffer 
(resting control) or 0.5 μg/mL CRP-XL for five minutes in an aggregometer prior to lysis in reducing sample treat-
ment buffer [RSTB; 69 mM sodium dodecyl sulphate, 5% (v/v) 2-mercaptoethanol, 10% (v/v) glycerol, and 25 mM 
Tris-HCl]. Subsequently, the platelet lysates were boiled at 90 °C for 10 minutes and analysed by SDS-PAGE in 
4–15% pre-cast gels (Bio-Rad, UK) and then transferred to a PVDF membrane (GE Healthcare, UK) using a 
Semi-Dry Transfer System (Bio-Rad, UK). The membrane was blocked with 5% (w/v) bovine serum albumin (BSA) 
in PBS with 0.1% (v/v) Tween-20 (PBS-T) for 1 hour at room temperature. Then it was incubated overnight at 4 °C 
with anti-TLR4 antibody (1/250 dilution) and for 1 hour at room temperature with anti-α-tubulin [B-7] or anti-
14-3-3ζ antibody (1/2000 dilution) (Santa Cruz Biotechnology, USA). 30 μg of HEK-293 or U251-NF-κB-GFP-Luc 
cell lysates were used as a TLR4-negative or -positive control respectively. The primary antibodies were detected by 
using Cy5-conjugated goat anti-mouse IgG (1/2500 dilution) (Thermo Fisher Scientific, UK) in a Typhoon 9400 
variable mode imager (GE Healthcare, UK) (488 V) and images were analysed using ImageJ.
Flow cytometry-based assays. Rabbit polyclonal FITC-conjugated anti-human fibrinogen antibodies 
(Dako, UK) were used to measure the level of fibrinogen binding as a marker for inside-out signalling to inte-
grin αIIbβ328 and PE-Cy5-conjugated mouse anti-human CD62P antibodies (BD Biosciences, UK) were used 
to measure the level of P-selectin exposure as a marker for α-granule secretion from platelets1,29. The human 
PRP was incubated with both the antibodies in HEPES-buffered saline (HBS: 150 mM NaCl, 5 mM KCl, 2 mM 
MgSO4.7H2O, and 10 mM HEPES, pH 7.4) for various time periods (0, 5, 20, 25, 30 and 50 minutes) with and 
without different concentrations of LPS chemotypes (LPSEC, LPSSM, and LPSRS). After preincubation, the platelets 
were exposed to modified Tyrode’s-HEPES buffer (vehicle) or 0.5 μg/mL CRP-XL, 0.25 μg/mL CRP-XL, 10 μM 
TRAP-6 (Abcam, UK), or 10 μM ADP (Sigma, UK) for various time points at room temperature or 37 °C. The 
platelets were then fixed using 0.2% (v/v) formyl saline and the level of fluorescence was measured using an 
Accuri C6 Flow cytometer (BD Biosciences, UK).
Platelet aggregation. The PRP was pre-activated with 0.5 μM ADP, 1 μM TRAP-6, or 0.1 μg/mL collagen 
(ChronoLog, UK) for five minutes prior to the addition of different ultrapure LPS chemotypes and incubation 
for another five minutes before initiating aggregation with 2 μM ADP, 10 μM TRAP-6, or 0.25 μg/mL collagen 
respectively. The aggregation was monitored for five minutes using a Chrono-Log (Model 700) aggregometer 
(USA) under constant stirring conditions at 37 °C.
Lactate dehydrogenase (LDH) assay. In order to determine if the LPS chemotypes have direct cytotoxic 
effects, a LDH cytotoxicity assay was performed using a LDH Cytotoxicity Assay Kit (Thermo Fisher Scientific, 
UK) according to the manufacturer’s instructions. Briefly, human PRP was incubated at 37 °C for 30 minutes 
prior to incubation with different concentrations of LPS chemotypes or a vehicle control (endotoxin free water) 
for 5 minutes. Subsequently, the reaction mixture provided in the kit was added to platelets and incubated for 
30 minutes and the reaction was stopped using a stop solution (provided in the kit). The positive control referred 
to in the results was supplied in the kit. The absorbance of the samples was read at 490 nm and 650 nm using a 
Fluostar Optima (BMG Labtech, Germany) spectrofluorometer.
Statistical analysis. All the data obtained in this study were analysed using GraphPad Prism 8. The data 
obtained from cell culture experiments were analysed using one-way ANOVA with the differences between treat-
ments investigated using a Bonferroni’s post-hoc test. Comparisons for relative band intensity in immunoblot 
images and TLR4 cluster:platelet ratios were analysed via Student’s t-test. Flow cytometry experiments were ana-
lysed using one-way ANOVA. The differences between the vehicle control (for experiments involving LPSEC) or 
the positive control (0.25 μg/mL, 0.5 μg/mL CRP-XL, 10 μM TRAP-6, or 10 μM ADP) and the experimental mean 
were tested for statistical significance through the use of a Dunnett’s post-hoc test. The normality of distribution 
was examined for all the datasets and non-parametric tests were used where appropriate (Friedman’s test with 
Dunn’s post-hoc test).
Data availability
The datasets generated and analysed in this study are available from the corresponding author on reasonable 
request.
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